Business Context and Reporting Period
Company: Conduit Pharmaceuticals Inc. (CDT)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: A clinical-stage specialty biopharmaceutical company acting as a conduit to develop and commercialize clinical assets, primarily focusing on HK-4 Glucokinase Activators and Myeloperoxidase inhibitors for autoimmune disorders and idiopathic male infertility. The company operates as an emerging growth company and smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(5,383) | $(8,935) | $(3,778) |
| Operating Expenses | $3,140 | $6,095 | $2,830 |
| Cash and Cash Equivalents | $219 (as of June 30, 2024) | $219 | $0 (as of June 30, 2023) |
| Working Capital Deficit | $(1,255) | $(1,255) | N/A |
| Accumulated Deficit | $(20,234) | $(20,234) | $(14,548) |
Debt and Liabilities: Total liabilities stood at $8.77 million as of June 30, 2024. Significant liabilities include a $5.74 million deferred commission payable (non-current) and a $0.8 million convertible promissory note payable.
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss for the six months ended June 30, 2024, increased to $8.9 million from $3.8 million in the same period in 2023. This represents a 136% increase.
- Operating Expenses: General and administrative expenses rose significantly to $5.9 million (YTD 2024) from $2.8 million (YTD 2023), driven by a $2.0 million increase in salaries/stock compensation and $0.9 million in D&O insurance amortization.
- Other Income/Expense: Non-operating expenses increased to $2.8 million (YTD 2024) from $0.9 million (YTD 2023). The primary driver was a $2.7 million expense related to the issuance of warrants in exchange for stockholder lock-up agreements.
- Cash Position: Cash and cash equivalents decreased from $4.2 million at December 31, 2023, to $0.2 million at June 30, 2024, due to operating cash burn of $3.9 million.
Outlook, Risks, and Subsequent Events
Liquidity and Going Concern: Management has determined that current cash resources are insufficient to fund operations for the next 12 months. The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern. The company is actively pursuing additional equity or debt financing.
Nasdaq Listing Deficiencies:
- Bid Price: Received a deficiency letter on August 12, 2024, for failing to maintain a $1.00 minimum bid price. The company has 180 days (until February 10, 2025) to regain compliance or risk delisting.
- Audit Committee: Received a notice regarding non-compliance with independent audit committee requirements due to a director resignation. The company has until May 13, 2025, to cure.
Subsequent Events (Post-June 30, 2024):
- AstraZeneca License: On August 7, 2024, entered into a license agreement with AstraZeneca for HK-4 Glucokinase activators and an MPO inhibitor. Consideration included a $1.5 million upfront payment and the issuance of 9.5 million shares of common stock.
- Debt Financing: On August 5, 2024, entered into a Senior Secured Promissory Note with Nirland Limited for $2.65 million (12% interest), accompanied by the issuance of 12.5 million shares of common stock.
Legal Proceedings: A claim by Strand Hanson Limited for $2 million and 6.5 million shares remains pending in the UK. The company disputes the claim and has not accrued a loss contingency.
Investor Verification Checklist
- Cash Runway: Verify the status of the $5 million commitment letter from Corvus Capital and the utilization of the new $2.65 million Nirland Note to assess immediate liquidity.
- Nasdaq Compliance: Monitor the stock price to determine if a reverse stock split or other measures are required to meet the $1.00 bid price requirement by February 2025.
- Dilution Impact: Review the impact of the 22 million shares issued in August 2024 (9.5M to AstraZeneca, 12.5M to Nirland) on existing shareholder equity.
- Deferred Fees: Confirm the repayment terms for the $5.74 million deferred commission payable, which is due from future financing proceeds.
- Restatement Context: Note that prior period financials (2023) were restated due to the reclassification of merger-related legal costs from expense to equity.